ODE II director
This article was originally published in The Tan Sheet
Executive Summary
FDA names Curtis Rosebraugh director of the Office of Drug Evaluation II after nine months as acting director of the office in the Center for Drug Evaluation and Research. He will oversee the divisions of Anesthesia, Analgesia and Rheumatology Products, Metabolism and Endocrinology Products and Pulmonary and Allergy Products. Rosebraugh from 2003-2005 served as deputy director of the Office of Nonprescription Products, with responsibilities including acting director of ONP's Division of Nonprescription Clinical Evaluation (1"The Tan Sheet" Feb. 10, 2003, In Brief). In 2005 he was named deputy director of the ODE II and became acting director in September 2007...
You may also be interested in...
New deputy in town
Curtis Rosebraugh, MD, took over as CDER Division of OTC Drug Products deputy director effective Jan. 27. Rosebraugh has previously worked as a medical officer in the Division of Pulmonary & Allergy Drug Products, which could affect the extent to which the OTC drug division attempts to initiate Rx-to-OTC switches of the remaining second-generation antihistamines. Rosebraugh replaces Linda Katz, MD, who left to head the Office of Cosmetics & Colors Sept. 3. Rosebraugh will report to Division of OTC Drug Products Director Charles Ganley, MD...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.